Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Observationeel onderzoek om de retentie van een Adalimumab Biosimilar (Hyrimoz®) bij IBD-patiënten in de praktijk te beoordelen (HYRISS)

19 november 2026 bijgewerkt door: Sandoz

Een multicenter, internationale, prospectieve, niet-interventionele, observationele studie om het behoud van de behandeling van een Adalimumab Biosimilar (Hyrimoz®) bij IBD-patiënten in de praktijk te beoordelen

An international, multicenter, non-interventional, prospective, post-authorization, descriptive, non-PASS, study.

Studie Overzicht

Toestand

Actief, niet wervend

Interventie / Behandeling

Gedetailleerde beschrijving

The main purpose of this non-interventional study is to assess patient retention with Hyrimoz® treatment up to 6 months after treatment initiation in Inflammatory Bowel Disease (IBD) patients.

Primary data will be collected at each data collection time point (visits will be according to local clinical practice). Data will be collected based on the information reported in the medical records. This study does not impose a therapy protocol, procedure or change in routine medical practice. Apart from self-administered questionnaires, no additional examinations or assessments are required, consequently there are no additional medical risks for the patients. The total duration of the study will be 36 months (3 years). The recruitment period will be for 2 years with individual patient follow-up for up to 1 year.

It is expected that patients will visit their physicians at regular intervals depending on local specific clinical practices. Four time points for data collection will be defined:

  • T0 (patient inclusion in the study and Baseline characteristics).
  • T1 (3-month follow-up ± 1 month).
  • T2 (6-month follow-up and primary criteria -2/+3 months).
  • T3 (12-month follow-up -3/+2 months).

Studietype

Observationeel

Inschrijving (Geschat)

562

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

      • Aalst, België
        • Sandoz Investigational Site Belgium
      • Antwerp, België
        • Sandoz Investigational Site Belgium
      • Bonheiden, België
        • Sandoz Investigational Site Belgium
      • Brussels, België
        • Sandoz Investigational Site Belgium
      • Eeklo, België
        • Sandoz Investigational Site Belgium
      • Ghent, België
        • Sandoz Investigational Site Belgium
      • Herentals, België
        • Sandoz Investigational Site Belgium
      • Kortrijk, België
        • Sandoz Investigational Site Belgium
      • Liège, België
        • Sandoz Investigational Site Belgium
      • Namur, België
        • Sandoz Investigational Site Belgium
      • Seraing, België
        • Sandoz Investigational Site Belgium
      • Sint-Niklaas, België
        • Sandoz Investigational Site Belgium
      • Tongeren, België
        • Sandoz Investigational Site Belgium
      • Amiens, Frankrijk
        • Sandoz Investigational Site France
      • Auxerre, Frankrijk
        • Sandoz Investigational Site France
      • Bayonne, Frankrijk
        • Sandoz Investigational Site France
      • Beauvais, Frankrijk
        • Sandoz Investigational Site France
      • Brest, Frankrijk
        • Sandoz Investigational Site France
      • Caen, Frankrijk
        • Sandoz Investigational Site France
      • Castelnau-le-Lez, Frankrijk
        • Sandoz Investigational Site France
      • Clermont-Ferrand, Frankrijk
        • Sandoz Investigational Site France
      • Clichy, Frankrijk
        • Sandoz Investigational Site France
      • Cornebarrieu, Frankrijk
        • Sandoz Investigational Site France
      • Créteil, Frankrijk
        • Sandoz Investigational Site France
      • Gien, Frankrijk
        • Sandoz Investigational Site France
      • Le Coudray, Frankrijk
        • Sandoz Investigational Site France
      • Le Kremlin-Bicêtre, Frankrijk
        • Sandoz Investigational Site France
      • Lille, Frankrijk
        • Sandoz Investigational Site France
      • Lyon, Frankrijk
        • Sandoz Investigational Site France
      • Marseille, Frankrijk
        • Sandoz Investigational Site France
      • Montpellier, Frankrijk
        • Sandoz Investigational Site France
      • Nancy, Frankrijk
        • Sandoz Investigational Site France
      • Neuilly-sur-Seine, Frankrijk
        • Sandoz Investigational Site France
      • Nice, Frankrijk
        • Sandoz Investigational Site France
      • Nîmes, Frankrijk
        • Sandoz Investigational Site France
      • Orléans, Frankrijk
        • Sandoz Investigational Site France
      • Paris, Frankrijk
        • Sandoz Investigational Site France
      • Pessac, Frankrijk
        • Sandoz Investigational Site France
      • Pierre-Bénite, Frankrijk
        • Sandoz Investigational Site France
      • Poitiers, Frankrijk
        • Sandoz Investigational Site France
      • Pringy, Frankrijk
        • Sandoz Investigational Site France
      • Reims, Frankrijk
        • Sandoz Investigational Site France
      • Rennes, Frankrijk
        • Sandoz Investigational Site France
      • Saint-Etienne, Frankrijk
        • Sandoz Investigational Site France
      • Saint-Nazaire, Frankrijk
        • Sandoz Investigational Site France
      • Sarrebourg, Frankrijk
        • Sandoz Investigational Site France
      • Toulouse, Frankrijk
        • Sandoz Investigational Site France
      • Tours, Frankrijk
        • Sandoz Investigational Site France
      • Troyes, Frankrijk
        • Sandoz Investigational Site France
      • Vandœuvre-lès-Nancy, Frankrijk
        • Sandoz Investigational Site France
      • Vénissieux, Frankrijk
        • Sandoz Investigational Site France

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 99 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

Patients for whom the investigator has decided to initiate treatment with Hyrimoz® in accordance with the approved SmPC and local clinical practice, will be eligible to participate in the study.

Beschrijving

Inclusion Criteria:

Patients must meet all of the following criteria at Baseline:

  • Patients initiating Hyrimoz® treatment.

  • Patients with a confirmed diagnosis (following local recommendations) of one of these indications: CD or UC.

  • Patients ≥ 18 years of age.

  • Patient in whom the decision to initiate Hyrimoz® (naïve population) or to switch (switch population) from reference adalimumab to Hyrimoz® was accorded with his physician before the proposal to participate in the study.

  • Patients meeting one of the following criteria:

    • Referred to as "switched patients": Patients treated continuously with adalimumab (other than Hyrimoz®) for at least 6 months, with an indication for continuing treatment with adalimumab at any therapeutic dose (physician's decision) and who have controlled stable disease for at least 3 months before study enrollment (according to the physician's criteria).
    • Referred to as "biologic-naive patients": Patients who had an inadequate response or contraindications to conventional therapy with no exposure to any biological medicine and targeted therapies and started Hyrimoz® as a first-line biologic therapy according to the summary of product characteristics (SmPC).
  • Patients able to complete and understand the self-administered questionnaires.

  • Patients who have been informed and have provided a signed written consent as per local regulations prior to participation in the study

Exclusion Criteria:

Patients fulfilling any of the following criteria are not eligible for inclusion in this study:

  • Patients enrolled in an ongoing interventional study.
  • Patients with any contraindications to Hyrimoz® according to the SmPC.
  • Patients at imminent risk of scheduled intestinal surgery (stenosis, strictures, internal fistula).
  • Use of any investigational drug in last 6 months prior to enrollment.
  • Patient received any biological medicine or targeted therapy, in case of " biologic-naive patient ",
  • Patient received adalimumab for less than 6 months or have controlled disease for less than 3 months, in case of "switched patient".

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Observatiemodellen: COHORT
  • Tijdsperspectieven: PROSPECTIVE

Cohorten en interventies

Groep / Cohort
Interventie / Behandeling
Hyrimoz

Patients prescribed with Hyrimoz

There is no treatment allocation. Patients administered Hyrimoz by prescription that have started as routine medical treatment will be enrolled.

Andere namen:
  • biosimilar van adalimumab

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Percentage of patients who remain on Hyrimoz® at 6 months after treatment initiation
Tijdsspanne: Up to 6 months

Assess patient retention with Hyrimoz® treatment up to 6 months after treatment initiation

Up to 6 months

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Percentage of patients who discontinue Hyrimoz
Tijdsspanne: 6 months, 12 months

Percentage of patients who discontinue Hyrimoz® at T2 and T3 due to:

  • Lack of efficacy.
  • Intolerance/Adverse event(s) or special scenario.
  • Patient's decision
  • Nocebo effect
  • Other reasons.
6 months, 12 months
Percentage of patients with high level of treatment satisfaction using TSQM-9 questionnaire
Tijdsspanne: 3 months, 6 months, 12 months

To assess patients' treatment satisfaction (based on 9-item Treatment Satisfaction Questionnaire for Medication [TSQM 9], the percentage of patients with high level of treatment satisfaction (score ≥ 39) will be collected.

The TSQM-9 is declined with 9 questions about patient treatment satisfaction. Each answer gives a number of points depending of the question and the answer. The final score is the sum of points in each question. This questionnaire score from 9 to 59 points. In HYRISS study, we estimate that patient with < 39 pts in TSQM-9 are considered with a low satisfaction for the medication (satisfaction under 60%).

3 months, 6 months, 12 months
Percentage of patients with high level of treatment adherence using adapted CQR5 questionnaire
Tijdsspanne: Baseline, 3 months, 6 months, 12 months

To assess adherence/compliance to treatment (based on 5 item Compliance Questionnaire for Rheumatology [CQR5] adapted for gastroenterologist), percentage of patients with high level of treatment adherence (score ≥ 15) using adapted CQR5 questionnaire will be collected.

The CQR5 is declined with 5 questions about patient compliance to the treatment. Each answer gives from 1 to 4 points depending of the answer. The final score is the sum of points in each question. This questionnaire score from 5 (very low compliance) to 20 points (very strong compliance).

Baseline, 3 months, 6 months, 12 months
Percentage of patients with the perception of a high level of disease activity using VAS scale
Tijdsspanne: Baseline, 3 months, 6 months, 12 months

To assess the patient's reported disease activity, percentage of patients with the perception of a high level (score ≥ 6) of disease activity will be collected using visual analog scale [VAS].

This visual analogue scale (VAS) is an instrument designed to document the disease activity. Patients are asked to rate their disease activity on a visual analogue scale (VAS): How active has your disease been this week? From 0 (Not active at all) to 10 cm (Extremely active).

Baseline, 3 months, 6 months, 12 months
Percentage of patients with a good perception about biosimilars using VAS scale
Tijdsspanne: Baseline

To assess the patient's reported perception about biosimilars at the inclusion visit, percentage of patients with a good perception (score ≥ 6) about biosimilars using VAS scale will be measured.

This visual analogue scale (VAS) is an instrument designed to document the perception of the patient about biosimilar. Patients are asked to rate their perception of biosimilar medicine on a visual analogue scale (VAS): Are you confident in using biosimilar? From 0 (I have no confidence at all) to 10 cm (I have a great confidence).

Baseline
Percentage of patients in remission
Tijdsspanne: Baseline, 3 months, 6 months, 12 months

Remission defined as Harvey-Bradshaw Index [HBI] ≤ 4 [for Crohn's Disease] or partial Mayo score ≤ 1 [for Ulcerative Colitis]

Baseline, 3 months, 6 months, 12 months
Crohn's disease activity measurement: Harvey Bradshaw Index [HBI]
Tijdsspanne: Up to 12 months

Crohn's disease activity will be measured with HBI score. Score is interpreted:

<4: Remission 4-7: Mild disease 8-16: Moderate disease >16: Severe disease

Up to 12 months
Ulcerative colitis activity measurement: partial Mayo calculation score
Tijdsspanne: Up to 12 months

Ulcerative colitis activity will be measured using partial Mayo calculation score. Score is interpreted: ≤ 1: Remission 2 - 4: Low activity disease 5 -6: Moderate disease 7 - 9: Severe disease

Up to 12 months
Pattern of Hyrimoz® utilization
Tijdsspanne: Up to 12 months

Pattern of Hyrimoz® utilization to be collected

Up to 12 months

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

16 februari 2023

Primaire voltooiing (Werkelijk)

15 december 2025

Studie voltooiing (Geschat)

1 maart 2027

Studieregistratiedata

Eerst ingediend

21 november 2022

Eerst ingediend dat voldeed aan de QC-criteria

21 november 2022

Eerst geplaatst (Werkelijk)

1 december 2022

Updates van studierecords

Laatste update geplaatst (Werkelijk)

20 november 2026

Laatste update ingediend die voldeed aan QC-criteria

19 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren